Lupin employees stock option plan 2016

- File or directory not found.

You are using an outdated browser. Please upgrade your browser to improve your experience. Hyderabad based NATCO Pharma Limited NSE: The net profit for the period, on a consolidated basis, was INR For the fourth quarter Q4 ended March 31st,the company recorded a net revenue of INR The profit after tax, on a consolidated basis, was recorded as INR The revenue and profit growth for the company during the financial year was driven primarily due to the sales of generic Oseltamivir product in the USA market and continued growth of domestic formulations business.

All results for the quarter and previous year FY have been restated to comply with Indian Accounting Standards Ind AS to make them comparable. A meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, the 30 th day of May, at Please further note that pursuant to the SEBI Prohibition of Insider Trading Regulations, TRADING WINDOW for dealing in the securities of the Company will be closed from 20 th May, to 01 st June, both days inclusive.

Trading window will be opened from 02 nd June, Natco Pharma Limited is pleased to announce that its partner Dr. Natco Pharma Limited NSE: Pomalidomide is sold by Celgene Inc. Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma a type of blood cancer who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Natco will market generic pomalidomide capsules under its brand name POMALID in India. Epclusa is a prescription medicine used to treat adults with chronic lasting a long time Hepatitis C Hep C genotype 1, 2, 3, 4, 5, or 6 infection with or without cirrhosis compensated. Natco has signed a nonexclusive licensing agreement with Gilead Sciences, Inc.

The revenue and profit growth for the company during the quarter was driven predominantly by the sales of Oseltamivir product in the USA market and includes profit sharing from our marketing partner. Click here for more details. A meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, the 14th day of February, at The unaudited financial Results for the quarter ended 31st December, and related matters.

To consider second Interim Dividend, if any, for the financial year and related matters etc. Please further note that pursuant to the SEBI Prohibition of Insider Trading Regulations, TRADING WINDOW for dealing in the securities of the Company will be closed from 3rd February, to 16th February, both days inclusive. Trading window will be opened from 17th February, At the end of the inspection, the facility received six observations, all of which are correctable and procedural, and which the company believes are minor in nature.

A copy of the observations is attached. The company will provide due justifications and corrective action plan within the next 15 working days to address the USFDA observations. Pursuant to the settlement of the Paragraph IV litigation, NATCO plans to launch this drug on November 1,or earlier under certain circumstances, through its marketing partner Breckenridge Pharmaceutical, Inc.

Natco and Breckenridge filed their ANDA with a Paragraph IV certification on the first-to-file date and expect to share day exclusivity with other ANDA first filers.

Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin.

Natco has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. Natco and Alvogen are not affiliated with Hoffman La-Roche Inc. Food and Drug Administration FDA for generic version of Armodafinil Tablets, 50 mg, mg, and mg.

NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. Food and Drug Administration FDA for generic version of Budesonide Capsules Enteric Coated3 mg.

NATCO and its marketing partner Alvogen plan to launch this product in the USA market immediately. The growth for the company during the quarter was driven primarily by increased sales of its formulation business.

A meeting of the Board of Directors of the Company is scheduled to be held on Friday, the 11th November, at Trading window will be opened from 14th November, NATCO Pharma Limited NSE: Patent and Trademark Office PTO has ruled in favor of its marketing partner, Mylan, in its inter partes review IPR proceeding and found all claims of U.

NSE - Corporate Announcements Details

Food and Drug Administration FDA for the inspection conducted, during the period February 8 — February 12,at its Chemical Division, Chennai, India named NATCO Organics Limited, prior to amalgamation into the company. Food and Drug Administration FDA for the inspection conducted at its drug manufacturing facility in Kothur Village, Mahaboob Nagar District, India, during the period February 29 — March 7, The Kothur facility predominantly caters to regulated international markets, including USA.

The net profit for the period, after tax and minority interest, on a consolidated basis, was INR The growth for the company was predominantly driven by increased sales of its oncology and hepatitis C products in India. NATCO and its marketing partner Alvogen are the first generic players to receive this approval.

Earlier in December,NATCO and Alvogen settled a patent infringement with Gilead Sciences, Inc. A meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 9th August, at Consideration of Employee Stock Option Scheme NATSOP under SEBI Share Based Employee Benefits Regulations, Please further note that TRADING WINDOW for dealing in the securities of the Company will be closed from 1st August, to 11th August, both days inclusive.

Trading window will be opened from 12th August, PSRK Prasad, Executive Vice President Corp Engineering Services and Mr. Srinivas Rao, Deputy General Manager, Environment Health and Safety, attended the event and received the award on behalf of the Company from Justice Dr. MYLhas received a tentative approval for its Abbreviated New Drug Application ANDA for Sorafenib Tablets, mg, with the U.

Food and Drug Administration USFDA. NATCO and Mylan have filed an ANDA containing a Paragraph IV certification for this product. NATCO manufactures this product at its facility in Kothur, Mahaboobnagar District, Telangana State, India.

Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc. For the 12 months ending Dec. The Board of NATCO Pharma Limited NPL met in Hyderabad today and adopted the consolidated audited accounts of the company for the year ended 31st March, NPL recorded an aggregate of Rs. The net profit, after tax, on a consolidated basis, was recorded as Rs. For the fourth quarter Q4 ended March 31st,the Company recorded a net revenue of Rs. The profit after tax, on a consolidated basis, was recorded as Rs.

A meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 26 th at It will be opened from 30th May, The High Court of Madras vide its Order dated 28th April,has sanctioned the Scheme of Amalgamation of NATCO Organics Limited, a Wholly Owned Subsidiary of the Company with NATCO Pharma Limited.

The agreement inter-alia provides for consideration towards goodwill, furniture and fixtures, Inventory etc. The Board of Directors of Natco Pharma Limited at their meeting held on the 30th of Marchapproved the sale of its Save Mart Pharmacy Store located in the USA.

The Save Mart Pharmacy Store is owned by Natco Pharma Inc. The company received Form observations for both facilities and believes them to be of minor in nature. The company has already sent response and compliance report for these observations and believes that there would be no adverse impact to its current or future pipeline products coming from these facilities.

Hyderabad based NATCO Pharma Limited has recorded an aggregate of Rs. The net profit, after tax, on a consolidated basis, was Rs. Click here for more Details.

Lupin - Grant of Options under Employees Stock Option Plan (ESOP)

In addition, Natco will receive a volume-limited license to sell generic Lenalidomide in the United States commencing in March The volume limit is expected to be a mid-single-digit percentage of the total Lenalidomide capsules dispensed in the United States during the first full year of entry. The volume limitation is expected to increase gradually each 12 months until March ofand is not expected to exceed one-third of the total Lenalidomide capsules dispensed in the U.

NATCO plans to launch this combination drug immediately, under its brand name Hepcinat LP, and through its strategic partners in India. It is indicated for the treatment of chronic hepatitis C CHC genotype 1 infection in adults. This single-tablet regimen is the first of its kind to offer significantly higher cure rates in Genotype-1 CHC infection compared to conventional therapies.

NATCO was the first licensed company to launch the generic version of this combination drug earlier in Nepal. Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus HCV genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.

Natco will market generic Daclatasvir under its own brand NATDAC, and through its strategic partners in India. Natco will launch Immediately in India at an MRP of Rs.

Tata Power - Wikipedia

FDA granted tentative approval to NATCO for the generic oseltamivir phosphate capsules on March 14, The Unit manufactures a few oncology related APIs at its Manali site. The Unit is also adequately insured for any losses it has incurred in fixed assets, raw materials and loss in production including work-in-progress.

Actual losses will be assessed once this natural calamity passes by, and the plant is back in full operational mode. Pursuant to Regulatin30 5 of SEBI Listing and Obligation Disclosure Requirements Regulations,please find below the details of the Key Managerial Personnel who have been jointly severally authorised by the Board of Directors of the Company:.

To determine the materiality of an even or information under this regulation and also making disclosures to stock Exchange s: Click Here For More Details. This is a decrease of about 8.

The growth in profit for the quarter was constrained due to delay in exports to South America. However, sales of domestic formulation segments, including Sofosbuvir, continue to do well. The company expects stronger sales growth with higher profitability, during H2 of FY AWACS is a market research agency with syndicated audit Pharma Trac.

These awards are instituted to recognise and reward top performers of the domestic pharma industry. This was the first edition of such awards, by an independent market research agency in India. ERLONAT was introduced by NATCO as the first generic Erlotinib in the year It was marketed at a fractional cost of trading signals rsi innovator drug, which benefitted thousands of non-small cell lung cancer and pancreatic cancer patients.

On behalf of the NATCO team, Mr. Srivastava-Vice President Sales and MarketingMr. Lalon Sen-Product Manager Lung Cancer Portfolio received the award on 7th October at Nehru Centre, Worli, Mumbai.

Venkatachaliah, former Chief Justice, Supreme Court of India. Affairs attended the event and received the award on trading signals rsi of the Company from the hands of the Rt.

Hyderabad based NATCO Pharma Limited informed that Foreign Investment Promotion Board FIPB has approved both of its Foreign Direct Investment FDI related proposals in its st Meeting held on July 13 th Board of Directors of Hyderabad based NATCO Pharma Limited approved and recommended to the members of the company a Sub-division of face value of its equity shares from Rs.

It also announced an aggregate consolidated net revenues joptionpane.showinputdialog int Rs. Although this is a decrease of about Click here to view Invitation. The Company awaits USFDA approval to launch the Product. Notice is hereby given that an Extraordinary General Meeting of the Members of Natco Pharma Limited will be held at 60 seconds binary options strategies methods Jubilee Hills International Centre, Road No.

Click her for a PDF with more information. The Board of Natco Pharma Limited NPL met in Hyderabad today and adopted the consolidated audited accounts of the company for the year ended 31st March, This includes two exceptional items:. The profits, after tax, on a consolidated basis, was recorded as Rs.

Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc. Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India. Natco plans to price its generic medicine earned leave encashment after technical resignation an MRP of INR 19, for a bottle of 28 tablets and expects to launch in India very soon.

Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries. Natco priced its generic medicine at an MRP of INR 19, for a bottle of 28 tablets in Nepal. NATCO markets generic sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India DCGI.

Natco is partnered with Alvogen in the USA for marketing of this product. The denial was issued pedagang forex yang berjaya March 9,in the case of Gilead Sciences, Inc. Natco Pharma Limited et al, No. The case remains pending in the District of New Jersey where the validity of U. This agreement allows Natco to expand access to these chronic hepatitis C medicines in 91 developing countries.

Under the license, Natco can set its own price for the custom stock for browning t bolt products it produces, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business binary options in the catch. MYLhas filed an Abbreviated New Drug Application ANDA for Sorafenib Tablets, mg, with the U.

Federal Drug Administration USFDA. Natco and its marketing partner believe that they are the first to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for days of marketing exclusivity upon receiving final FDA approval. The net profit, after tax, on a consolidated basis, before exceptional item was Rs.

There was a one-time exceptional charge of Rs. As a result, the net profit, after tax, on a consolidated basis, was Rs. Federal Drug Administration USFDAthrough its respective marketing partners in the USA. Novartis sells Fingolimod 0.

The said SLP was filed by Bayer against Union of India, Natco Pharma Ltd. The net profit, after tax, on a consolidated basis, improved to Rs. Click here tutorial on online trading in india view Intimation. Natco and Breckenridge have entered into a settlement regarding the ANDA with Cephalon, the terms of which are confidential.

The Facility was classified as acceptable. The Company has made proposed commitments and corrective actions based on the minor and routine observations during inspection. We continue to manufacture and sell products in the US. We strongly deny all adverse speculations against the Company. BPIhas filed an Abbreviated New Drug Application ANDA for Everolimus 0.

Natco and BPI believe that its Paragraph IV ANDA was filed on the First-to-File date and expects to be the only generic that is entitled to the day exclusivity period. Novartis AG sells Everolimus 0. Food and Drug Administration US FDA.

In North America, Copaxone is marketed by Teva Neuroscience, Inc. The Nexavar issue dates back to March 9,when the then Controller General of Patents issued the first-ever CL to the Company to manufacture an affordable generic version of sorafenib tosylate, the anti-cancer sgx nikkei 225 index futures trading hours for which Bayer had obtained a patent.

The Board eur rate graph live NATCO Pharma met at Hyderabad today and adopted the consolidated audited accounts of the company for the year ended 31st March, The net profit after tax for the quarter ended 31st March, was Rs.

The Company had earned a profit after tax of Blu ray option on computers. Natco and Breckenridge believe that the ANDA was filed on the first-to-file date, providing days of exclusivity. Teva Cephalon sells Bendamustine Hydrochloride under Brand name TREANDA, used as a chemotherapy medicine in oncology segment.

Natco Pharma Limited and Alvogen, who have partnered with respect to the first substantially complete Abbreviated New Drug Application ANDA filed with the U. Natco Pharma Limited et al, In it, Circuit Judges Chen and Prost agreed with Natco and Alvogen that the earlier expiring Orange Book listed patent qualifies as an obviousness-type double patenting reference for the later expiring Orange Book lupin employees stock option plan 2016 patent.

The case has been remanded to the District how to make money as a member on runescape of New Jersey where Natco and Alvogen will continue to challenge the validity of U.

Natco may have First to File approval status for the Abbreviated New Drug Application ANDAcontingent upon successful litigation outcome. Natco today issues a clarification with regard to launch of generic Copaxone.

Natco confirms the final decision as to when or whether and pricing of generic Copaxone is launched in the US rests with its Partner Mylan. Natco remains committed and working working of bombay stock exchange pdf take steps and x3 albion prelude making money guide the necessary resources to ensure that a quality generic US FDA approved Copaxone is made available to patients suffering from Multiple Sclerosis upon market formation.

The Stock Exchange will be duly informed whenever such a decision is made in the future.

We continue to believe that the sole Indian process patent is invalid, as reinforced by the outcomes of numerous other legal proceedings. We also are pursuing other challenges against this patent. The hearing on this petition has been set for 5 March Further, the Indian Patent Office stock option sale 1099-b to grant two additional patent applications, which would have covered the copolymer-1 product.

Court of Appeals for the Federal Circuit last July. Hyderabad based NATCO Pharma Limited had exhibited improved operating results for the quarter ended 31st December, Aggregate revenues went up to Rs. On a consolidated basis, the revenues for the quarter went up to Rs. The Board has recommended payment of an interim dividend of Rs. Hyderabad based NATCO Pharma Limited has recorded higher profits for the quarter ended 30th September, For the quarter ended 30th September,on a consolidated revenue base of Rs.

The growth has been driven by value-added formulation exports during the quarter. Click here to view EGM Notification. Hyderabad based NATCO Pharma Limited has clocked an aggregate of Rs.

Employee Stock Options Plan

Revenues for the quarter ended on 30th June,as against Rs. API exports and finished dosage pharmaceutical formulations exports continue to drive the growth. This would essentially mean that NATCO could launch the generic Copaxone — through its marketing partner — Mylan Inc. NATCO Pharma Limited is pleased to announce the employee stock option schemes of marketing approval for its Rizatriptan Benzoate Maxalt-MLD — orally disintegrating tablets, 5 mg and 10 mg base.

The Company has already commenced shipments of the product, which is being launched by its marketing partner — Breckenridge Pharmaceuticals.

Rizatriptan is used to treat migraine headaches with or without aura warning signs that occur prior to the onset of a migraine headache. The Board of NATCO Pharma met at Hyderabad today to adopt the stand-alone audited accounts of the company for the year ended 31st March, The net profit after how fast can i receive money from paypal for the quarter ended 31st March, was The profit would have been higher, but for an additional non-cash deferred tax liability of Rs.

Hyderabad based NATCO Pharma Limited has recorded improved operating results for the quarter and nine-months calculate no of days between two dates in excel on 31st December, The Board has also recommended payment of an interim dividend of Rs.

The increase in revenues was driven by API and formulation exports. NATCO Pharma Limited is pleased to announce the approval by US FDA, of its Abbreviated New Drug Application ANDA for Lansoprazole Delayed Release Capsules, USP, 15 mg and 30 mg. The Board of Directors of the Hyderabad based NATCO Pharma Limited, met today and took on record the operational performance of the Company for the quarter and half-year ended on 30th September, The Company has recorded a consolidated revenue base of Rs.

The profit after tax at Rs. The growth in revenues and profitability was driven by increased sales of APIs and exports of finished dosage pharmaceutical formulations. For the half-year ended on 30th September,the consolidated revenues stood at Rs. The profit after tax for the half year stood at Rs. NATCO Pharma Limited, Hyderabad, is pleased to announce the elevation of Mr. Thirty five year old Rajeev has many accomplishments to his credit. Honors Double Major in Economics and History from Tufts University, Boston, U.

Rajeev has been instrumental in helping the company evolve business strategies that ultimately resulted in NATCO becoming one of the fastest growing companies in the Indian Pharma space. This strategy has paid off and today NATCO has several para IV and firstto-file opportunities ready and the company is in a position to encash multi-Billion marketing opportunities. Rajeev would be incharge of all day-to-day operations of the Company and would oversee all functional areas.

The Hyderabad based NATCO Pharma Limited has recorded increased revenues and profits for the financial year ended on 31st March, The Board met at Hyderabad today and approved the accounts. The Company has recorded aggregate revenues of Rs. Bhagwati, former Chief Justice of India and Member, UN Human Rights Commission. Natco Pharma Limited is the first Indian Pharma Company which received the award from His excellency Dr.

Venkatachaliah, Former Chief Justice of India, His excellency Mr. Natco Pharma Limited has bagged the award under stiff competition which shows and proves its commitment to the Corporate Social Responsibility. The Hyderabad based NATCO Pharma Limited is pleased to announce the granting of a compulsory licence to it, under the provisions of Section 84 of the Indian Patents Act, for Sorafenib Tosylate Brand Name: Nexavar owned by Bayer Corporation.

Nexavar is the first-line treatment for liver and kidney cancer. The Compulsory License, first of its kind granted, enables NATCO to sell the drug at a price not exceeding Rs. The license is valid till the expiry of the patent — The order also makes it obligatory for NATCO to supply the drug free of cost to at least needy and deserving patients per year. NATCO welcomes this order and opines that this opens up a new avenue of availability of life savings drugs at an affordable price to the suffering masses in India.

Hyderabad based NATCO Pharma Limited has posted an aggregate revenues of Rs. The company posted a net profit, after tax, of Rs. The revenues for the quarter ended on 31st December, stand at Rs. The net profit after tax, for the same period stand at Rs.

The Board had recommended the payment of an interim dividend of Rs. The Hyderabad based NATCO Pharma Limited has recorded increased turnover and profitability for the quarter and half-year ended on 30th September, The stand-alone revenues, for the quarter ended on 30th September, grew from Rs. The net profit after tax, for the same period, grew from Rs. The net profit, after tax, for the same period grew from Rs.

The growth was driven by revenues from API division, from Rs. Hyderabad based NATCO Pharma Limited has entered into an exclusive agreement with Mabxience, the bio-similar division of Chemo Sa Lugano, Switzerland, an integrated healthcare multinational involved into different fields of pharmaceutical business, including bio-similars and branded pharmaceuticals.

Under the agreement, NATCO will purchase four mAb drug substances from Chemo and use the same for manufacturing finished dosage pharmaceutical formulations. Three of these products viz.

Oncology is the largest therapy area within the mAb market, with eight marketed products. The mAb market is highly innovative and a key trend has been the move from murine to humanized and fully human antibodies, with insignificant generic presence.

With the product combinations chosen by NATCO, the mAb initiative is likely to be completed in a period of 24 to 36 months. Hyderabad based NATCO Pharma Limited had recorded increased profits for the first quarter April — June of the current fiscal The consolidated revenues for the quarter ended 30th June, stood at Rs Crores and would have been higher, but for the sale of one of the retail pharmacy stores in the USA.

During the current quarter, the company had filed an ANDA for Lapatinib Ditosylate mg tablets. The company believes that it has a first -to-file opportunity for this product.

The company has tied-up with Lupin Limited for supply and marketing of this product. With this product, the Company has five para IV challenges, out of which four products are with a first-to-file opportunity. NATCO Pharma Limited is pleased to announce the launch, in the United States of America, of the generic version of Anastrazole 1 mg.

The company recorded an EPS of Rs. The company is confident of gaining a reasonable share of the market. Hyderabad based NATCO Pharma is pleased to announce the commercial launch of its brand — BENDIT — Bendamustine — a novel agent in the treatment of Chronic Lymphocytic Leukemia CLLmostly seen in the elderly people.

Bendamustine is a unique hybrid cytotoxic, which is mechanistically distinct from the existing options. Response rates to Bendamustine are reported to be high and durable, and the therapy is seen as a superior and tolerable first line option in the treatment of CLL. Bendit is the generic version of Treanda, the innovator brand, which is priced at around Rs. Bendit is aggressively priced at Rs. The Hyderabad based NATCO Pharma Limited is pleased to announce the acceptance of its Abbreviated New Drug Application for the generic version of Oseltamivir Phosphate capsules.

Oseltamivir Phosphate is used in the treatment of bird and swine-flu infections. NATCO has tied up with the Luxemburg based Alvogen IPCO S. The Board of the Hyderabad based NATCO Pharma Limited had recommended an interim dividend of Rs. The Board, which met in Hyderabad today, considered the financial results of the Company for the quarter and nine months ended on 31st December, The Company recorded revenues of Rs.

The company earned a net profit, after tax, of Rs. The company has accounted for a loss of nearly Rs. Of-late, however, owing to budgetary restrictions, there have been significant reductions in the reimbursements.

However, this sale would not have any significant effect on the revenues and profitability of NATCO Pharma Limited. With this sale, NATCO Pharma Limited now owns and operates only one retail pharma store -through its wholly owned subsidiary — NATCO Pharma Inc.

This store is doing well and is not dependent on Medicaid reimbursements. NATCO Pharma Limited is pleased to announce that the Government of India has stayed the suspension of its Albupax manufacturing product license.

Albupax is a nanotechnology based drug and is the first generic version of the international brand. Albupax consists of Paclitaxel in an Albumin-bound nanoparticle form and is used in the treatment of breast cancer.

Among other things, NATCO pleaded that:. NATCO is thankful to the Government for its decision in this regard. NATCO stands by its commitment to provide high quality and life saving drugs at affordable price to Indian patients. All rights reserved Terms of Use Privacy Policy Sitemap. We manufacture niche and complex Pharma products under the pressure of expectation. Unaudited financial Results for the quarter ended 30th June, To Consider Interim Dividend, if any, for the year Convening of 33rd Annual General Meeting for the financial year Pursuant to Regulatin30 5 of SEBI Listing and Obligation Disclosure Requirements Regulations,please find below the details of the Key Managerial Personnel who have been jointly severally authorised by the Board of Directors of the Company: Name Designation E-mail Id Mr.

Appa Rao Interim Chief Financial Officer svvn natcopharma. NATCO Pharma LimitedNATCO House, Road No. The two approvals given are for: Issue and Allotment of Eligible Securities to Qualified Institutional Buyers QIBs up to Rs.

This includes two exceptional items: The trademark is the property of the respective Owner. All trademarks are the property of their respective owners. SLP filed by Bayer against Natco has been dismissed by Hon'ble Supreme Court of India 12 December Natco Pharma Ltd. Lakhs Particulars For the quater ended For the quater ended Stand-alone gross revenues Stand-alone profit after tax Consolidated gross revenues Consolidated profit after tax The Board has recommended payment of an interim dividend of Rs.

NATCO records higher profits 14 November Hyderabad based NATCO Pharma Limited has recorded higher profits for the quarter ended 30th September, NATCO receives USFDA approval, all set to launch Lansoprazole 19 December NATCO Pharma Limited is pleased to announce the approval by US FDA, of its Abbreviated New Drug Application ANDA for Lansoprazole Delayed Release Capsules, USP, 15 mg and 30 mg.

Shipments of this product will commence immediately. Rajeev, who joined the Board inwas till now the Chief Operating Officer. The growth was driven by increased API sales and formulation exports. NATCO records increased turnover,profitability 09 November The Hyderabad based NATCO Pharma Limited has recorded increased turnover and profitability for the quarter and half-year ended on 30th September, The Company recorded an earnings per share of Rs.

NATCO is exploring the possibility of introducing this product in international markets as well. Among other things, NATCO pleaded that: The testing methods used to evaluate nanotechnology based protein-bound formulations are highly complex and variable.

An appropriate test method needs to be employed to test such products. NATCO would announce its future plans shortly. All rights reserved Terms of Use Privacy Policy Sitemap Designed by: